新型冠状病毒感染低风险人群的血液筛查策略初探  

Blood screening strategy for SARS-CoV-2 among low risk populations

作　　者：邬林枫[1] 王立林[1] 邬旭群[1] 赵钰 刘衡[1] 赵俊鹏 李然 杜丹丹[1] 许晓绚[1] 曾劲峰[1] WU Linfeng;WANG Lilin;WU Xuqun;ZHAO Yu;LIU Heng;ZHAO Junpeng;LI Ran;DU Dandan;XU Xiaoxuan;ZENG Jinfeng(Shenzhen Blood Center,Shenzhen 51803,China)

机构地区：[1]深圳市血液中心,广东深圳518035

出　　处：《中国输血杂志》2021年第4期343-346,共4页Chinese Journal of Blood Transfusion

基　　金：2020年度广东省医学科研基金项目(A2020259);深圳市科创委课题(JCYJ20170307092008192);深圳市医学重点学科建设经费资助(SZXK070)。

摘　　要：目的分析新型冠状病毒(SARS-CoV-2)2种不同血液筛查策略在低风险感染人群中的应用价值,为血液检测策略制定提供参考。方法采取2种血液SARS-CoV-2抗体筛查策略:1)所有标本先检测总抗体,总抗阳性标本再检测IgG和IgM;2)所有标本仅检测IgG和IgM。对880份献血者标本进行抗体筛查,同时平行检测SARS-CoV-2核酸,抗体反应性标本应用中和试验确证。计算2种不同抗体筛查策略的灵敏度、特异度以及真阳性率。结果 880份献血者标本中,SARS-CoV-2核酸反应性标本0例;9例(1.02%,9/880)总抗体反应性标本中确证阳性4例;26例(2.95%,26/880)IgG或IgM任一反应性标本中确证阳性3份。结论先检测总抗体后检测IgG+IgM的检测策略,灵敏度和特异性优于仅检测IgG+IgM,或许可作为SARS-CoV-2感染低风险人群的血液抗体筛查策略。Objective To analyze the viability of 2 different blood screening strategies against SARS-CoV-2 in low risk populations, so as to provide references for the formulation of blood screening strategy. Methods Two screening strategies for antibodies against SARS-CoV-2 were adopted: 1) the total antibody were initially screened for all samples, and the antibody IgG and IgM were retested in those primary positive samples;2) only antibody test of IgG and IgM for all samples. And SARS-CoV-2 nucleic acid was detected in parallel. Reactive samples was confirmed by neutralization test. The sensitivity, specificity and true positive rate of two strategies were calculated. Results None was positive for SARS-CoV-2 nucleic acid among 880 samples. Four truly positive samples were implicated in 9(1.02%, 9/880) initially reactive samples in total antibody test;3 in 26(2.95%, 26/880) initially IgG or IgM reactive samples.Conclusion The first strategy is superior to the second strategy in the sensitivity and specificity, and is recommended for the detection of SARS-CoV-2 antibody in low risk populations.

关 键 词：新型冠状病毒 SARS-CoV-2 核酸检测 总抗体检测 血液筛查策略 

分 类 号：R446.6[医药卫生—诊断学] R373.1[医药卫生—临床医学]